Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | F13A1 | P00488 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
| ▸ | TGM1 | P22735 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26906132 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL30001283 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL29770796 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL29827202 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL5728977 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL29827014 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL12276853 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL5728974 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL20633608 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL12274909 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3NR1H2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517708-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-03-30 | — | — | EP | claimed |
| US-20040006135-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-08 | — | — | US | claimed |
| WO-2004000355-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-12-31 | — | — | WO | claimed |
| EP-1192952-A2 | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-04-03 | — | — | EP | claimed |
| EP-4323369-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-02-21 | — | — | EP | disclosed |
| US-20230365594-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365594-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365594-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-11661431-B2 | Thienopyrrole compounds | GILEAD SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661431-B2 | Thienopyrrole compounds | GILEAD SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661431-B2 | Thienopyrrole compounds | GILEAD SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20220389034-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2022-12-08 | — | — | US | disclosed |
| EP-1517708-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-03-30 | — | — | EP | disclosed |
| US-20040006135-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-08 | — | — | US | disclosed |
| WO-2004000355-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| EP-1192952-A2 | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| US-6051575-A | RESPIRATORY SYSTEM DISORDERS; SKIN DISORDERS; ANTIINFLAMMATORY AGENTS | SCHERING CORPORATION (US) | 2000-04-18 | — | — | US | disclosed |
| US-5968929-A | USEFUL IN THE TREATMENT OF CHRONIC AIRWAY DISEASES SUCH AS ASTHMA | SCHERING CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0937069-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998018788-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1998-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365594-A1 | THIENOPYRROLE COMPOUNDS | SSB, TPMT, LCP2 | CHRM2 3105/4885CHRM1 3889/4885CHRM3 3374/4885 |
| US-20040006135-A1 | Combination treatment for depression and anxiety | TACR1, NPSR1, HTR3A | CHRM2 421/4885CHRM1 397/4885CHRM3 164/4885 |
| US-11661431-B2 | Thienopyrrole compounds | SSB, TPMT, LCP2 | CHRM2 3105/4885CHRM1 3889/4885CHRM3 3374/4885 |
| US-20220389034-A1 | THIENOPYRROLE COMPOUNDS | SSB, TPMT, LCP2 | CHRM2 3105/4885CHRM1 3889/4885CHRM3 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.